Advanced

Quality assessment for prostate-specific antigen (PSA) in relation to ERSPC: report of the PSA Committee

Blijenberg, BG; Lilja, Hans LU ; Neels, H and Stenman, UH (2003) In BJU International1999-01-01+01:00 92(Suppl. 2). p.66-70
Abstract
Objective To assess the application of a quality control scheme for total prostate-specific antigen (PSA) as used for participants of the European Randomized Study for Screening of Prostate Cancer (ERSPC) during 1996-2002. Methods From 1996, the first complete year being 1997, an external scheme was organized by the Dutch Quality Assessment Foundation especially for the ERSPC. This scheme consists of one control round every 2 months with two different human serum samples and is only meant to compare the recovery of methods. From 1998 an internal scheme was also applied by adding two distinct samples to every round. Results Initially there was a wide variation (coefficient of variation of +/-15% at threshold PSA of 4.0 ng/mL) among all... (More)
Objective To assess the application of a quality control scheme for total prostate-specific antigen (PSA) as used for participants of the European Randomized Study for Screening of Prostate Cancer (ERSPC) during 1996-2002. Methods From 1996, the first complete year being 1997, an external scheme was organized by the Dutch Quality Assessment Foundation especially for the ERSPC. This scheme consists of one control round every 2 months with two different human serum samples and is only meant to compare the recovery of methods. From 1998 an internal scheme was also applied by adding two distinct samples to every round. Results Initially there was a wide variation (coefficient of variation of +/-15% at threshold PSA of 4.0 ng/mL) among all ERSPC participants who were all using the Tandem assay (Hybritech Inc, USA). After introducing the internal scheme the performance of some intra-ERSPC group comparisons for PSA and the introduction of the completely automated Beckman-Access analyser in 2001 there was state-of-the-art precision for PSA of 5% in the 2002 surveys. Conclusion The ERSPC group measurements of PSA have considerably improved since 1996 because of the application of a quality-assessment scheme and with the introduction of complete automation of the PSA assay. Both findings are in line with earlier developments in clinical chemistry. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
BJU International1999-01-01+01:00
volume
92
issue
Suppl. 2
pages
66 - 70
publisher
Blackwell Science Ltd
external identifiers
  • wos:000187880900014
  • scopus:0347756698
ISSN
1464-4096
DOI
10.1111/j.1465-5101.2003.04401.x
language
English
LU publication?
yes
id
30e092ac-ccc1-4b10-9331-41fec70838a8 (old id 291166)
date added to LUP
2007-08-24 11:56:30
date last changed
2018-01-07 05:25:50
@article{30e092ac-ccc1-4b10-9331-41fec70838a8,
  abstract     = {Objective To assess the application of a quality control scheme for total prostate-specific antigen (PSA) as used for participants of the European Randomized Study for Screening of Prostate Cancer (ERSPC) during 1996-2002. Methods From 1996, the first complete year being 1997, an external scheme was organized by the Dutch Quality Assessment Foundation especially for the ERSPC. This scheme consists of one control round every 2 months with two different human serum samples and is only meant to compare the recovery of methods. From 1998 an internal scheme was also applied by adding two distinct samples to every round. Results Initially there was a wide variation (coefficient of variation of +/-15% at threshold PSA of 4.0 ng/mL) among all ERSPC participants who were all using the Tandem assay (Hybritech Inc, USA). After introducing the internal scheme the performance of some intra-ERSPC group comparisons for PSA and the introduction of the completely automated Beckman-Access analyser in 2001 there was state-of-the-art precision for PSA of 5% in the 2002 surveys. Conclusion The ERSPC group measurements of PSA have considerably improved since 1996 because of the application of a quality-assessment scheme and with the introduction of complete automation of the PSA assay. Both findings are in line with earlier developments in clinical chemistry.},
  author       = {Blijenberg, BG and Lilja, Hans and Neels, H and Stenman, UH},
  issn         = {1464-4096},
  language     = {eng},
  number       = {Suppl. 2},
  pages        = {66--70},
  publisher    = {Blackwell Science Ltd},
  series       = {BJU International1999-01-01+01:00},
  title        = {Quality assessment for prostate-specific antigen (PSA) in relation to ERSPC: report of the PSA Committee},
  url          = {http://dx.doi.org/10.1111/j.1465-5101.2003.04401.x},
  volume       = {92},
  year         = {2003},
}